HCPLive Network

FDA Requests Removal of Generic Budeprion XL 300 mg

 
WEDNESDAY, Dec. 5 (HealthDay News) -- The U.S. Food and Drug Administration has concluded that generic Budeprion XL 300 mg (extended-release bupropion hydrochloride, manufactured by Impax Laboratories and distributed by Teva Pharmaceuticals) cannot be considered therapeutically equivalent to the brand-name product, according to a perspective piece published online Dec. 5 in the New England Journal of Medicine.

Noting that Budeprion XL 300 mg was approved based on extrapolation of the results of a bioequivalence study of Budeprion XL 150 mg and Wellbutrin XL 150 mg, Janet Woodcock, M.D., from the Center for Drug Evaluation and Research at the FDA in Rockville, Md., and colleagues reviewed new data providing direct comparative pharmacokinetic analyses of Budeprion XL 300 mg with Wellbutrin XL 300 mg. They conducted a bioequivalence study involving 24 healthy fasting volunteers in a single-dose crossover design.

The researchers found that the extent of bupropion absorption for the generic product was 86 percent of that of the brand-name product, and that the mean peak plasma concentration observed after Budeprion XL 300 mg administration was only 75 percent of that observed after administration of Wellbutrin XL 300 mg. In certain participants, the maximum plasma concentration and area under the plasma concentration curve for Budeprion XL were less than 40 percent of those for Wellbutrin. The time to peak drug concentration in the blood was shorter for Budeprion XL (four hours) than for Wellbutrin XL (five hours).

"We at the FDA are therefore changing our bioequivalence recommendations for extended-release bupropion products and have asked other manufacturers of 300-mg extended-release bupropion products to conduct additional bioequivalence studies," the authors write. "We do not believe that the results of the FDA study should cause concern regarding the overall reliability of the agency's approval process for generic drugs, including the use of extrapolation, when scientifically appropriate."
 

Full Text

 
Copyright © 2012 HealthDay. All rights reserved.
 
 

Further Reading
A 3-year study of a product meant to help patients dealing with a wide range of conditions including diabetes, hypertension, and weight loss showed positive results according to manufacturer EnteroMedics, Inc.
As national and international health agencies and other groups shift their focus during the current outbreak of the Ebola virus from treatment of those patients with the virus to preventing further large scale events, a team of researchers has reported some success in looking at how Ebola compromises an infected person’s immune system.
For many patients with chronic conditions such as rheumatoid arthritis, medication adherence is often one of the most challenging aspects of the treatment process, especially when the medications prescribed by their health care professional are prohibitively expensive. A study from Manchester University recently showed that many patients with rheumatoid arthritis are not taking some of their most critical medicines due to rising drug costs.
The leading cause of cancer related deaths in both men and women is lung cancer. The 5-year survival rate of lung cancer is only 16%, as 75% of patients with lung cancer are presented with symptoms of advanced disease.
Overconfident people are better at convincing others that they're more talented than they really are, and therefore are more likely to get promotions and reach high-level positions, according to British researchers. Their findings were published online Aug. 27 in PLOS ONE.
Progress has been made toward widespread adoption of electronic health records, although there are still barriers to adoption of advanced use of EHRs, according to a report published by the Robert Wood Johnson Foundation.
For patients with hypertension, finding the right course of treatment can be critically important especially when other health factors are taken into consideration.
More Reading